2025-07-29 – Press Releases – www.prnewswire.com
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ — Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis…
